Table 4.
Univariate Cox Regression Analysis for DFS
| Characteristics | HR (95% CI) | P- value | |
|---|---|---|---|
| Gender | Male vs female | 0.600 (0.310–1.163) | 0.130 |
| ∆CEA% | < −30.29% vs > −30.29% | 0.656 (0.366–1.177) | 0.157 |
| ∆CA199% | < 20.30% vs > 20.30% | 0.550 (0.298–1.013) | 0.055 |
| STBC score | 0–1 vs 2 | 0.419 (0.220–0.800) | 0.008 |
| Pathological vascular invasion | Absent vs present | 0.456 (0.180–1.156) | 0.098 |
| Pathological lymphatic invasion | Absent vs present | 0.463 (0.182–1.174) | 0.105 |
| Pathological perineural invasion | Absent vs present | 0.554 (0.286–1.074) | 0.080 |
| Pathological CRM | Negative vs positive | 1.392 (0.192–10.107) | 0.744 |
| ypT staging | (0–2) vs (3–4) | 0.429 (0.228–0.807) | 0.009 |
| ypN staging | Negative vs positive | 0.606 (0.326–1.126) | 0.113 |
Abbreviations: yp, pathologic status after neoadjuvant chemoradiotherapy; ∆CEA %, (post-chemoradiotherapy CEA – pre-chemoradiotherapy CEA)/pre-chemoradiotherapy CEA*100%; ∆CA199 %, (post-chemoradiotherapy CA199 – pre-chemoradiotherapy CA199)/ pre-chemoradiotherapy CA199*100%; STBC score, serum tumor biomarkers change score.